



## (51) International Patent Classification:

G01N 33/50 (2006.01) G01N 33/569 (2006.01)  
C12Q 1/68 (2006.01)

## (21) International Application Number:

PCT/EP2013/058226

## (22) International Filing Date:

19 April 2013 (19.04.2013)

## (25) Filing Language:

English

## (26) Publication Language:

English

## (30) Priority Data:

|            |                            |    |
|------------|----------------------------|----|
| 61/808,406 | 4 April 2013 (04.04.2013)  | US |
| 61/811,321 | 12 April 2013 (12.04.2013) | US |
| 61/813,380 | 18 April 2013 (18.04.2013) | US |

(71) Applicant (for all designated States except US): **NOVARTIS AG** [CH/CH]; Lichtstrasse 35, CH-4056 Basel (CH).

## (72) Inventors; and

(71) Applicants (for US only): **BORELL, Hubert** [FR/CH]; c/o Novartis Institutes for BioMedical Research, Postfach, CH-4002 Basel (CH). **GARDIN, Anne** [FR/CH]; c/o Novartis Institutes for BioMedical Research, Postfach, CH-4002 Basel (CH). **JIN, Yi** [CN/CH]; c/o Novartis Institutes

for BioMedical Research, Postfach, CH-4002 Basel (CH). **LEGANGNEUX, Eric** [FR/CH]; c/o Novartis Institutes for BioMedical Research, Postfach, CH-4002 Basel (CH). **UFER, Mike** [DE/CH]; c/o Novartis Institutes for BioMedical Research, Postfach, CH-4002 Basel (CH).



(74) Agent: **HUTCHISON, John**; Novartis Pharma AG, Patent Department, CH-4002 Basel (CH).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,

[Continued on next page]

## (54) Title: IDENTIFYING PATIENT RESPONSE TO S1P RECEPTOR MODULATOR ADMINISTRATION

Figure 1-1 Time-dependent biotransformation of [<sup>14</sup>C]BAF3121 μM [<sup>14</sup>C]BAF31210 μM [<sup>14</sup>C]BAF312

(57) Abstract: The invention provides a method of assessing the appropriate therapeutic dose of 1-{4-[1-(4-cyclohexyl-3-trifluoromethyl-benzyloxyimino)-ethyl]-2-ethyl-benzyl}-azetidine-3-carboxylic acid to administer to a patient in need thereof, comprising the steps of: (i) testing whether or not the patient has the poor metabolizer genotype; and (ii) if the patient does not have the poor metabolizer genotype, administering -{4-[1-(4-cyclohexyl-3-trifluoromethyl-benzyloxyimino)-ethyl]-2-ethyl-benzyl}-azetidine-3-carboxylic acid, or a pharmaceutically acceptable salt thereof, to the patient at the standard therapeutic dose; and (iii) if the patient does have the poor metabolizer genotype, either (a) administering 1-{4-[1-(4-cyclohexyl-3-trifluoromethyl-benzyloxyimino)-ethyl]-2-ethyl-benzyl}-azetidine-3-carboxylic acid, or a pharmaceutically acceptable salt thereof, to the patient at a therapeutic dose below that of the standard therapeutic dose; or (b) not administering 1-{4-[1-(4-cyclohexyl-3-trifluoromethyl-benzyloxyimino)-ethyl]-2-ethyl-benzyl}-azetidine-3-carboxylic acid, or a pharmaceutically acceptable salt thereof, to the patient.



EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, **Published:**

LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK,

SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,

GW, ML, MR, NE, SN, TD, TG).

— *with international search report (Art. 21(3))*

**Declarations under Rule 4.17:**

— *as to non-prejudicial disclosures or exceptions to lack of novelty (Rule 4.17(v))*